Bristol Myers to buy RayzeBio for $4.1 billion



Bristol Myers Squibb announced on Tuesday in a statement that it has struck a definitive merger deal with RayzeBio, Inc. worth $4.1 billion or $62.50 per share in cash. The boards of directors of both…
About the author:

Get involved!

Fai trading in gruppo!
L'unica Academy di trading completamente gratuita per gli utenti FpMarkets

Comments

Ancora nessun commento